Literature DB >> 9630550

Repeated electroconvulsive shock extends the duration of enhanced gene expression for BDNF in rat brain compared with a single administration.

T S Zetterström1, Q Pei, D G Grahame-Smith.   

Abstract

Brain-derived neurotrophic factor (BDNF) is known to modulate synaptic function as well as to promote neuronal growth in the adult brain. The aim of the present study was to compare the duration of electroconvulsive shock (ECS)-induced BDNF gene expression following a single shock (acute ECS) to the more clinically relevant situation, where repeated shocks (chronic ECS) are administered. For this purpose, we have used quantitative in situ hybridisation with a 35S-labelled oligonucleotide probe complementary to mRNAs encoding genes for all forms of BDNF. The results confirm previous studies that the administration of ECS increases BDNF mRNA abundance in parts of rat brain with particularly marked changes in the granule cell layer of the dentate gyrus. We also for the first time show the long lasting nature of the increase in BDNF mRNA abundance measured after chronic ECS, i.e., significant increases in BDNF mRNA persisted up to 48 h after the last shock. Acute ECS at 6 h after the shock produced a slightly more pronounced effect on BDNF mRNA abundance than chronic ECS 6 h after the last shock. However, this change was not detectable already 24 h after a single ECS. These results indicate that repeated ECS induces adaptive changes in BDNF mRNA expression. Copyright 1998 Elsevier Science B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630550     DOI: 10.1016/s0169-328x(98)00077-1

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  24 in total

1.  Effects of repeated minimal electroshock seizures on NGF, BDNF and FGF-2 protein in the rat brain during postnatal development.

Authors:  Jinsook Kim; Karen Gale; Alexei Kondratyev
Journal:  Int J Dev Neurosci       Date:  2010-02-17       Impact factor: 2.457

Review 2.  Consequences of brain-derived neurotrophic factor withdrawal in CNS neurons and implications in disease.

Authors:  Abigail Mariga; Mariela Mitre; Moses V Chao
Journal:  Neurobiol Dis       Date:  2016-03-22       Impact factor: 5.996

3.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

4.  Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins.

Authors:  Sung-Soo Jang; Han Gil Jeong; Hee Jung Chung
Journal:  J Vis Exp       Date:  2017-08-15       Impact factor: 1.355

5.  Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects.

Authors:  F Pilar-Cuéllar; R Vidal; A Pazos
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

6.  Electroconvulsive shock enhances striatal dopamine D1 and D3 receptor binding and improves motor performance in 6-OHDA-lesioned rats.

Authors:  Elissa M Strome; Athanasios P Zis; Doris J Doudet
Journal:  J Psychiatry Neurosci       Date:  2007-05       Impact factor: 6.186

Review 7.  The neurobiology of treatment response to antidepressants and mood stabilizing medications.

Authors:  L Trevor Young; David Bakish; Serge Beaulieu
Journal:  J Psychiatry Neurosci       Date:  2002-07       Impact factor: 6.186

Review 8.  Neuropeptides in depression: role of VGF.

Authors:  Smita Thakker-Varia; Janet Alder
Journal:  Behav Brain Res       Date:  2008-10-15       Impact factor: 3.332

Review 9.  Target identification for CNS diseases by transcriptional profiling.

Authors:  C Anthony Altar; Marquis P Vawter; Stephen D Ginsberg
Journal:  Neuropsychopharmacology       Date:  2008-10-15       Impact factor: 7.853

Review 10.  Repetitive transcranial magnetic stimulation : does it have potential in the treatment of depression?

Authors:  Frank Padberg; Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.